Clinical Trial Update: Study of PPI-668, BI 207127 and Faldaprevir, With and Without Ribavirin, in the Treatment of Chronic Hepatitis C [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating combinations of PPI-668, BI 207127, and faldaprevir with and without ribavirin for chronic hepatitis C has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• BI 207127 (BI-207127)
• Faldaprevir (faldaprevir)
• PPI-668
• Ribavirin (ribavirin)

Snippet

Sponsor: Presidio Pharmaceuticals, Inc. | Conditions: Chronic Hepatitis C | Phase 2 | Status: COMPLETED